Journal article
Case report: Metastatic BRAF V600E-mutated adult Wilms' tumor with robust response to BRAF/MEK inhibitor therapy
Frontiers in oncology, Vol.14, p.1376270
07/15/2024
DOI: 10.3389/fonc.2024.1376270
PMCID: PMC11373342
PMID: 39234402
Abstract
Nephroblastoma or Wilms' tumor (WT) is the most common pediatric renal malignancy but rare in adults. Treatment protocols for adults are typically extrapolated from pediatric guidelines, but there are no standard guidelines for adults due to the rarity of the disease. However, next-generation sequencing has led to new therapeutic options for adult WT patients. We present the first case to our knowledge of a recurrent adult WT treated with dual BRAF/MEK-targeted therapy, which showed initial robust clinical response and was well tolerated.
Details
- Title: Subtitle
- Case report: Metastatic BRAF V600E-mutated adult Wilms' tumor with robust response to BRAF/MEK inhibitor therapy
- Creators
- Matthew R. Kroll - Rush University Medical CenterCherry Au - Rush University Medical CenterJessica Slostad - Rush University Medical CenterTrevor N. Christ - Rush University Medical CenterSam G. Papas - Rush University Medical CenterAlan Tan - Rush University Medical Center
- Resource Type
- Journal article
- Publication Details
- Frontiers in oncology, Vol.14, p.1376270
- DOI
- 10.3389/fonc.2024.1376270
- PMID
- 39234402
- PMCID
- PMC11373342
- ISSN
- 2234-943X
- eISSN
- 2234-943X
- Publisher
- Frontiers Media Sa
- Number of pages
- 6
- Language
- English
- Date published
- 07/15/2024
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985237607902771
Metrics
1 Record Views